/
We are a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase, or IRAK4 and FMS-like tyrosine kinase 3 or FLT3. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma, …
$4.63
$0.35 (-7.03%)
EOD Jul 17, 2026
The business is unprofitable at the operating level (-60.50% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 13.4% YoY. The question is whether this is cyclical or a structural shift.
At 926x earnings, the current multiple leaves limited room for execution misses or growth deceleration. Negative free cash flow of -$27M. The business is consuming cash, not generating it.
926.0x earnings. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$7M
▼ -13.4% YoY
Net Income (TTM)
-$21M
▲ +82.5% YoY
Op. Margin
-100.17%
▲ +347.8pp YoY
ROIC
-56.33%
▲ +118.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$29M
▲ +31.2% YoY
Op. Cash Flow (TTM)
-$29M
▲ +31.2% YoY
Net Debt
-$14M
Net Cash Position
Cash & Equiv.
$15M
5Y CAGR: -2.7%
Continue Research
At a P/E of 926.0, Curis (CRIS)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Curis scores 39/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Curis scores 39 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -100.2% operating margin and a -56.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh CRIS's valuation and scores 39/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.